Cytokinetics Stock Investor Sentiment
| CYTK Stock | USD 52.22 0.20 0.38% |
About 53% of Cytokinetics' institutional investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Cytokinetics suggests that some traders are interested. Cytokinetics' investing sentiment shows overall attitude of investors towards Cytokinetics.
Panic Vs Confidence
53
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Cytokinetics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Cytokinetics.
News SentimentBullish | Hype SentimentBearish | Insider SentimentDisposing |
Cytokinetics Historical Sentiment
Although Cytokinetics' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Cytokinetics, such as negative comments on social media and news outlets, may cause fear in the market and push Cytokinetics' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Cytokinetics.
Cytokinetics |
Cytokinetics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Cytokinetics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Cytokinetics Historical Investor Sentiment
Investor biases related to Cytokinetics' public news can be used to forecast risks associated with an investment in Cytokinetics. The trend in average sentiment can be used to explain how an investor holding Cytokinetics can time the market purely based on public headlines and social activities around Cytokinetics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Cytokinetics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Cytokinetics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Cytokinetics news discussions. The higher the estimate score, the more favorable the investor's outlook on Cytokinetics.
Far too much social signal, news, headlines, and media speculation about Cytokinetics that are available to investors today. That information is available publicly through Cytokinetics media outlets and privately through word of mouth or via Cytokinetics internal channels. However, regardless of the origin, that massive amount of Cytokinetics data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Cytokinetics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Cytokinetics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Cytokinetics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Cytokinetics alpha.
Cytokinetics Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Disposition of 5422 shares by Malik Fady Ibraham of Cytokinetics at 53.05 subject to Rule 16b-3 | 09/13/2024 |
2 | Disposition of 5000 shares by Robert Blum of Cytokinetics at 6.67 subject to Rule 16b-3 | 09/16/2024 |
3 | Disposition of 11500 shares by Robert Blum of Cytokinetics at 59.49 subject to Rule 16b-3 | 10/11/2024 |
4 | Disposition of 5300 shares by Malik Fady Ibraham of Cytokinetics at 7.96 subject to Rule 16b-3 | 10/15/2024 |
5 | Cytokinetics, Incorporated EVP Fady Ibraham Malik Sells 7,300 Shares | 10/17/2024 |
6 | Disposition of 4452 shares by Wierenga Wendall of Cytokinetics at 7.37 subject to Rule 16b-3 | 10/28/2024 |
7 | Cytokinetics Reports Third Quarter 2024 Financial Results | 11/06/2024 |
8 | Cytokinetics Coverage Initiated by Analysts at Royal Bank of Canada | 11/11/2024 |
9 | FMR LLC Bolsters Stake in Cytokinetics Inc | 11/13/2024 |
10 | ADAR1 Capital Management, LLC Expands Stake in Cellectar Biosciences Inc | 11/15/2024 |
11 | A win for Apellis, a setback for Astellas | 11/19/2024 |
12 | Bayer Acquires Rights for Cardiovascular Drug From CYTK in Japan | 11/20/2024 |
13 | FDA Accepts Bayers Application for Label Expansion of Nubeqa | 11/22/2024 |
14 | Disposition of 742 shares by Wierenga Wendall of Cytokinetics at 7.37 subject to Rule 16b-3 | 11/25/2024 |
15 | Cytokinetics director Wendall Wierenga sells 37,100 in stock | 11/26/2024 |
Check out Cytokinetics Hype Analysis, Cytokinetics Correlation and Cytokinetics Performance. For more information on how to buy Cytokinetics Stock please use our How to buy in Cytokinetics Stock guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.38) | Revenue Per Share 0.03 | Quarterly Revenue Growth 0.225 | Return On Assets (0.30) | Return On Equity (5.72) |
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytokinetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.